Cryo-Cell International Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Cryo-Cell International Inc Unternehmen

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Unternehmensinformationen

BörsenkürzelCCEL

Name des UnternehmensCryo-Cell International Inc

IPO-datumApr 04, 1994

CEOMr. Mark L. Portnoy

Anzahl der mitarbeiter82

WertpapierartOrdinary Share

GeschäftsjahresendeApr 04

Addresse700 Brooker Creek Blvd

StadtOLDSMAR

BörseNYSE American Consolidated

LandUnited States of America

Postleitzahl34677

Telefon18137492104

Websitehttps://www.cryo-cell.com/

BörsenkürzelCCEL

IPO-datumApr 04, 1994

CEOMr. Mark L. Portnoy

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. David I. Portnoy

Chairman of the Board, Co-Chief Executive Officer

1.59M

+1.44%

Mr. Oleg Mikulinsky

Chief Information Officer

104.35K

--

Mr. Harold D. Berger, CPA

Independent Director

57.90K

+14.88%

Ms. Jill M. Taymans

Chief Financial Officer, Vice President - Finance

45.40K

--

Mr. Daniel Mizrahi

Independent Director

30.63K

--

Dr. Joanne Kurtzberg, M.D.

Medical Director

--

Ms. Irene Smith

Executive Assistant / Office Manager

--

Mr. Mark L. Portnoy

Co-Chief Executive Officer, Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. David I. Portnoy

Chairman of the Board, Co-Chief Executive Officer

1.59M

+1.44%

Mr. Oleg Mikulinsky

Chief Information Officer

104.35K

--

Mr. Harold D. Berger, CPA

Independent Director

57.90K

+14.88%

Ms. Jill M. Taymans

Chief Financial Officer, Vice President - Finance

45.40K

--

Mr. Daniel Mizrahi

Independent Director

30.63K

--

Dr. Joanne Kurtzberg, M.D.

Medical Director

--

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Processing and storage fees

7.87M

98.71%

Public banking revenue

82.08K

1.03%

Product revenue

20.91K

0.26%

Keine Daten

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Processing and storage fees

7.87M

98.71%

Public banking revenue

82.08K

1.03%

Product revenue

20.91K

0.26%

Aktionärsstatistik

Aktualisiert: Sat, Aug 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Portnoy (David I)

19.78%

Portnoy (Mark)

11.61%

Fleishman (Adam)

6.32%

Hamilton Lane Advisors, LLC

5.09%

SFI Advisors LLC

2.05%

Andere

55.15%

Aktionäre

Anteil

Portnoy (David I)

19.78%

Portnoy (Mark)

11.61%

Fleishman (Adam)

6.32%

Hamilton Lane Advisors, LLC

5.09%

SFI Advisors LLC

2.05%

Andere

55.15%

Aktionärstypen

Aktionäre

Anteil

Individual Investor

40.67%

Investment Advisor

5.87%

Private Equity

5.09%

Hedge Fund

0.74%

Investment Advisor/Hedge Fund

0.65%

Research Firm

0.02%

Andere

46.96%

Institutionelle Beteiligung

Aktualisiert: Tue, Jul 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q2

38

4.28M

53.09%

-6.66K

2025Q1

39

4.88M

60.37%

-1.40K

2024Q4

36

4.88M

60.35%

-45.33K

2024Q3

31

4.73M

58.53%

-190.45K

2024Q2

32

4.72M

57.24%

-175.49K

2024Q1

34

4.70M

56.72%

-231.88K

2023Q4

36

4.69M

56.61%

-257.13K

2023Q3

34

4.69M

56.58%

-265.51K

2023Q2

34

4.80M

57.00%

-223.23K

2023Q1

36

5.70M

67.38%

-813.20K

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Portnoy (David I)

1.57M

19.44%

--

Feb 28, 2025

Portnoy (Mark)

935.77K

11.58%

--

Feb 28, 2025

Fleishman (Adam)

509.00K

6.3%

--

Feb 28, 2025

Hamilton Lane Advisors, LLC

409.73K

5.07%

--

Jun 30, 2025

SFI Advisors LLC

165.30K

2.05%

--

Mar 31, 2025

The Vanguard Group, Inc.

118.23K

1.46%

+1.28K

+1.09%

Mar 31, 2025

The MassMutual Trust Company, FSB

111.03K

1.37%

--

Mar 31, 2025

Mikulinsky (Oleg)

104.35K

1.29%

--

Feb 28, 2025

Berger (Harold D)

50.40K

0.62%

--

Feb 28, 2025

Geode Capital Management, L.L.C.

45.23K

0.56%

+5.37K

+13.47%

Mar 31, 2025

Verbundene ETFs

Name

Anteil

Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 9.69M USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Jan 29, 2025

CCEL.NB Interim Cash Dividend of gross USD 0.25 paid on Feb 28, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Feb 28, 2025

Feb 14, 2025

Oct 31, 2024

CCEL.NB Interim Cash Dividend of gross USD 0.25 paid on Nov 29, 2024 going ex on Nov 15, 2024

Nov 15, 2024

Nov 29, 2024

Nov 15, 2024

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

Cryo-Cell International Inc

4.850USD

Cryo-Cell International Inc

4.850

Übersicht

Unternehmen

Finanzen

Analyse